
MSD licenses Lp(a) heart drug from Hengrui in $2bn deal
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the HRS-5346 candidate outside the Greater China region …